Stuart Curbishley

Stuart was awarded his PhD by the University of Birmingham in 2005 after which his group developed a programme of early-phase clinical trials, leading the development of dendritic cell therapy for primary liver cancer. Stuart directed the University of Birmingham’s GMP manufacturing unit, overseeing the development of new ATMPs, extending to T cell products, stromal cells, chondrocytes, and dendritic cells. Now playing a leading role in developing Adthera bio, Stuart brings his expertise in closing manufacturing processes and developing sustainable, scalable solutions to the projects his team work on.